The global Antibody Drug Conjugates market size is expected to be worth around US$ 10.93 billion by 2030, according to a new report by Vision Research Reports.
The global Antibody Drug Conjugates market size was valued at US$ 2.57 billion in 2020 and is anticipated to grow at a CAGR of 35.9% during forecast period 2021 to 2030.
Growth Factors
Increasing incidence of cancer coupled with growing geriatric population are likely to drive the market for Antibody-Drug Conjugates (ADC). Furthermore, major technological advancements are also contributing to drive the growth. According to the World Health Organization (WHO), the number of people aged 65 years and above, is projected to reach 16% of the total population by 2050 from 7% in 2000. Aging has become a substantial risk factor for numerous diseases including cancer and others. Hence, the growing geriatric population is expected to drive growth of the market over the forecast period.
Until 2018, four ADCs were available in the market, namely, Adcetris, Kadcyla, Besponsa, and Mylotarg. Due to appropriate targeting and improved technology, ADCs have been gaining a lot of attention from both small and large pharmaceutical companies. Currently there are more than 50 ADCs in clinical trials and it has been projected that during the forecast period three to four ADCs will be commercialized in the area of refractory Hodgkin lymphoma, glioblastoma, small cell lung cancer, breast cancer, and ovarian cancer. It has been observed that the maximum number of clinical trials are being conducted for lymphoma.
Report Highlights
ADCs combine the sensitive and unique targeting abilities of antibodies which allows sensitive discrimination between cancer tissues and healthy tissues with the cell-killing ability of cytotoxic drugs. All the four ADCs available in the market are approved for the treatment of cancer.
Based on application, the market is categorized into blood cancer, breast cancer, ovarian cancer, lung cancer, and brain tumor. Breast cancer was the largest revenue generating segment in 2017 owing to the factors, such as high prevalence of breast cancer on global scale and commercial availability of Kadcyla in most of the major regions.
Rising prevalence of cancer is one of the major drivers accelerating the antibody drug conjugates market. According to the World Health Organization(WHO), in 2018, the most common types of cancer were breast cancer with 2.09 million cases, lung cancer with 2.09 million cases, colorectal cancer with 1.80 million cases, prostate cancer with 1.28 million cases, skin cancer with 1.04 million cases, and stomach cancer with 1.03 million cases.
Based on technology, the market is bifurcated into cleavable and non-cleavable linkers. These two are the most predominant technologies used to link cytotoxic anticancer agents’ payloads. For instance, two of the bestselling ADCs- Adcetris and Kadcyla, contains cleavable and non-cleavable linkers.
Production of suitable chemical linkers between the monoclonal antibody and the cytotoxic drug is one of the main challenges in manufacturing effective and safe ADCs. The synthesis of linker chemistry is relatively complex and numerous features must be balanced to guarantee efficacy, eventually, the type of linker being used forms the release profile of the cytotoxin.
North America was the largest revenue generating region, followed by Europe. The major factor attributing for their continued dominance includes the presence of significant market players, such as Seattle Genetics, Roche, Pfizer, and AbbVie. North America is the most well-established market in terms of the usage of ADCs coupled with well-established healthcare infrastructure, and patient awareness.
Report Coverage | Details |
Market Size | US$ 10.93 billion by 2030 |
Growth Rate | CAGR of 35.9% From 2021 to 2030 |
Base Year | 2020 |
Historic Data | 2017 to 2020 |
Forecast Period | 2021 to 2030 |
Segments Covered | Application, Technology |
Regional Scope | North America, Latin America, Europe, Asia Pacific, MEA |
Companies Mentioned | Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Pfizer, Inc.; AstraZeneca; Gilead Sciences, Inc.; Astellas Pharma; Seagen, Inc.; Daiichi Sankyo Company Ltd.; GlaxoSmithKline Plc; ADC Therapeutics |
Key Players
Seattle Genetics, Inc .;Takeda Pharmaceutical Company Limited; Pfizer Inc.; F. Hoffmann-La Roche Ltd.; and AbbVie Inc.
Market Segmentation
Application Outlook
Blood Cancer
Leukemia
Lymphoma
Breast Cancer
Ovarian Cancer
Lung Cancer
Brain Tumor
Technology Outlook
Cleavable Linker
Non-cleavable Linker
Regional Outlook
North America
U.S.
Canada
Europe
U.K.
Germany
Asia Pacific
Japan
China
Latin America
Brazil
Middle East & Africa
South Africa
The Antibody Drug Conjugates market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Antibody Drug Conjugates market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Antibody Drug Conjugates market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Antibody Drug Conjugates market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Antibody Drug Conjugates market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Antibody Drug Conjugates capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Antibody Drug Conjugates by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Antibody Drug Conjugates market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Antibody Drug Conjugates market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Antibody Drug Conjugates market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Antibody Drug Conjugates industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Antibody Drug Conjugates market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Antibody Drug Conjugates market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Antibody Drug Conjugates market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Antibody Drug Conjugates market. These factors have benefited the growth of the global market for Antibody Drug Conjugates. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Antibody Drug Conjugates. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Antibody Drug Conjugates are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
Primary Sources
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Antibody Drug Conjugates Market, By Application
7.1. Antibody Drug Conjugates Market, by Application, 2021-2028
7.1.1. Blood Cancer
7.1.1.1. Market Revenue and Forecast (2016-2028)
7.1.2. Breast Cancer
7.1.2.1. Market Revenue and Forecast (2016-2028)
7.1.3. Ovarian Cancer
7.1.3.1. Market Revenue and Forecast (2016-2028)
7.1.4. Lung Cancer
7.1.4.1. Market Revenue and Forecast (2016-2028)
7.1.5. Brain Tumor
7.1.5.1. Market Revenue and Forecast (2016-2028)
Chapter 8. Global Antibody Drug Conjugates Market, By Technology
8.1. Antibody Drug Conjugates Market, By Technology, 2021-2028
8.1.1. Cleavable Linker
8.1.1.1. Market Revenue and Forecast (2016-2028)
8.1.2. Non-cleavable Linker
8.1.2.1. Market Revenue and Forecast (2016-2028)
Chapter 9. Global Antibody Drug Conjugates Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, by Application (2016-2028)
9.1.2. Market Revenue and Forecast, By Technology (2016-2028)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, by Application (2016-2028)
9.1.3.2. Market Revenue and Forecast, By Technology (2016-2028)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, by Application (2016-2028)
9.1.4.2. Market Revenue and Forecast, By Technology (2016-2028)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Application (2016-2028)
9.2.2. Market Revenue and Forecast, By Technology (2016-2028)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, by Application (2016-2028)
9.2.3.2. Market Revenue and Forecast, By Technology (2016-2028)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, by Application (2016-2028)
9.2.4.2. Market Revenue and Forecast, By Technology (2016-2028)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, by Application (2016-2028)
9.2.5.2. Market Revenue and Forecast, By Technology (2016-2028)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, by Application (2016-2028)
9.2.6.2. Market Revenue and Forecast, By Technology (2016-2028)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Application (2016-2028)
9.3.2. Market Revenue and Forecast, By Technology (2016-2028)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, by Application (2016-2028)
9.3.3.2. Market Revenue and Forecast, By Technology (2016-2028)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, by Application (2016-2028)
9.3.4.2. Market Revenue and Forecast, By Technology (2016-2028)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, by Application (2016-2028)
9.3.5.2. Market Revenue and Forecast, By Technology (2016-2028)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, by Application (2016-2028)
9.3.6.2. Market Revenue and Forecast, By Technology (2016-2028)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Application (2016-2028)
9.4.2. Market Revenue and Forecast, By Technology (2016-2028)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, by Application (2016-2028)
9.4.3.2. Market Revenue and Forecast, By Technology (2016-2028)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, by Application (2016-2028)
9.4.4.2. Market Revenue and Forecast, By Technology (2016-2028)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, by Application (2016-2028)
9.4.5.2. Market Revenue and Forecast, By Technology (2016-2028)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, by Application (2016-2028)
9.4.6.2. Market Revenue and Forecast, By Technology (2016-2028)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Application (2016-2028)
9.5.2. Market Revenue and Forecast, By Technology (2016-2028)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, by Application (2016-2028)
9.5.3.2. Market Revenue and Forecast, By Technology (2016-2028)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, by Application (2016-2028)
9.5.4.2. Market Revenue and Forecast, By Technology (2016-2028)
Chapter 10. Company Profiles
10.1. Seattle Genetics, Inc .
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Takeda Pharmaceutical Company Limited
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Pfizer Inc.
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. F. Hoffmann-La Roche Ltd.
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. AbbVie Inc.
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
Glossary of Terms